



# Studying Amorphous Pharmaceutical Materials by Powder X-Ray Diffraction and other Solid-State Techniques

Shawn Yin, George Crull, Martha Davidovich, Denette Murphy, Anisha Patel, Beth Sarsfield, Ray Scaringe, Boris Shekunov and John Grosso

Solid-State Chemistry Group  
Analytical Research and Development  
Research and Development  
Bristol-Myers Squibb Co.  
New Brunswick, New Jersey, USA

**PPXRD-8, May 6<sup>th</sup>, 2009**



Bristol-Myers Squibb Company



# Outline

- **Pharmaceutical amorphous and crystalline substances**
- **Understanding pharmaceutical amorphous materials**
- **Pharmaceutical “Amorphous Challenges”**
- **Amorphous characterization**
  - **Powder X-ray diffraction**
  - **Other Techniques**





# Pharmaceutical Solids

- **Pharmaceutical solid substances:**
  - API, API Intermediates, excipients, mixtures (granules, tablets), etc.
- **Physical states:**
  - crystalline, amorphous, their mixtures (semi-crystalline) and liquid crystal
- **Properties:**
  - stability, solubility, crystallinity, hygroscopicity, dissolution rate, bioavailability, powder properties, etc.









# Crystalline and Amorphous Solids

- **Crystalline solid:**
  - Solid having a regularly repeating arrangement of the positions of atoms or chemical entity (atoms and molecules).
- **Amorphous solid:**
  - An amorphous solid is a solid in which there is no long-range order of the positions of the atoms. Usually, amorphous materials have some short-range order at the atomic length scale due to the nature of chemical bonding.



# Amorphous and Crystalline Solids



Sq



# Amorphous Pharmaceutical Solids

- **API**

- Most of the pharmaceutical oral dosage products on the market contain crystalline API; only several products contain amorphous API (like Cefuroxime Axetil and BMS's Coumadin - Warfarin Sodium)
- ICH guideline defines amorphous as one of the API polymorph forms (ICH Guideline Q6A (2), included solvation products and amorphous forms for API polymorphism)
- Amorphous API, in general, can not easily be handled, controlled and processed, compared to its crystalline form(s)

- **Excipients**

- Many commonly used pharmaceutical excipients are in amorphous state (like cellulose, starch, PVA, fumed silica, povidone, etc.)
- In general, amorphous excipients are well characterized





# Amorphous vs. Crystalline Solids

## - Key Pharmaceutical Relevant Properties\*

Properties	Crystalline API	Amorphous API
Energy State	Low	High
Physical Stability	High	Low
Chemical Stability	High	Low
Hygroscopicity	Low	High
Purity	High	Low
Characterizability	High	low
Process Scalability	High	Low
Process Reproducibility	High	Low
Solubility	Low	High
Dissolution Rate	Slow	Fast
Bioavailability	Low	High
Process and Formulation Process-ability	Good	Poor
Development and Manufacturing Risks	Low	High

\* Generally true



# The Main Pharmaceutical “Amorphous Challenges”



- **Physical stability (as it is thermodynamically unstable)**
  - Keeping desirable amorphous component for better bioavailability
  - Identifying a co-processing agent to stabilize amorphous API to achieve best bioavailability and understanding the mechanism
  - Avoiding unwanted amorphous component in crystalline API synthesis and product formulation processes
  - Identifying the key kinetic stability factors to avoid conversions
- **Physical characterization**
  - Amorphous material, usually, is poorly understood and characterized
  - Detecting the trace level of amorphous API in crystalline matrix or vice versa
  - Identifying characterizable performance/quality indicator(s) for QbD
  - Understanding the interaction between API and co-processing agent(s)
- **Processing and Handling**
  - Extra efforts, comparing to crystalline API
- **No amorphous API until it is necessary!**





# Common Amorphous Physical Characterization Techniques



- **(sub)-Molecular (or Micro-) level techniques:**
  - **Vibrational spectroscopy: Raman, FT-IR, Near IR**
  - **ssNMR spectroscopy**
  - **Electronic microscopy (TEM and STM)**
- **Particular (or Meso-) level techniques:**
  - **PXRD**
  - **Thermal analysis (DSC and MDSC, TSC)**
  - **Optical/Electronic microscopy (SEM, EDOX)**
- **Bulk (or Macro-) level techniques:**
  - **Moisture and solvent sorption**
  - **Solubility**
  - **Powder techniques: particle size distribution, particle morphology, surface area, density, flowability, compressibility, wettability, etc.**



# Characterizing Amorphous Solids by PXRD




- PXRD is an extremely powerful tool for studying crystalline materials
- Due to the lack of three dimensional structure, the typical amorphous PXRD patterns are characterized by one or two halos in the range we usually measure; no simulated PXRD pattern for amorphous material (except the PDF or other modeling methods)
- The shape, position, intensity and numbers of “amorphous halo” are unique to each amorphous material and may reflect the degree of material’s “amorphization” (disorder); different amorphous patterns for different amorphous state?
- Unlike commonly used for crystalline materials, it is difficult to use PXRD as a “finger-print” technique, for amorphous materials
- **A material’s amorphous characteristics (like the degree of disordering) are usually confirmed by diffraction techniques (commonly PXRD), prior to the measurements by other techniques**





# An Amorphous API PXRD Pattern





# Indomethacin Grinding Experiments\*





Fig. 5. XRPD patterns of unground and ground  $\gamma$  indomethacin (*bottom to top*); 4, 12, 18, 24, 30, 45, and 60 min of grinding. Note: no significant change in peak width is observed with increased grinding time.

\*S. Bates, G. Zografi, D. Engers K. Morris, K. Crownley & A. Newman, *Pharm Res.*, Vol. 23, No. 10, 2333-2349 (2006)






# Amorphous Excipient PXRD Patterns



Encyclopedia of Pharmaceutical Technology, J. Swarbrick (ED), 3<sup>rd</sup> edition, pp4106




# Unwanted Amorphous Component in Crystalline API




# Undesired Amorphous Component in Crystalline API



BMS-644950-01 Lot: 57608-049 Ca Salt Water Isotherm@25°C (without Drying)



BMS-644950 Lot: 57608-049 Water Isotherm@25°C







- Moisture is a powerful tool to detect the amorphous component, even at trace levels
- Materials which have amorphous are usually hygroscopic
- In this case:
  - Particles swell slightly during water adsorption
  - Samples dried @ elevated T take up more H<sub>2</sub>O than those dried @ ambient
  - Structural changes caused by higher T drying are not reversible (by PXRD)





# Stabilizing the Amorphous API


## - Two Component Amorphous System





# Trace Crystalline API in Amorphous Matrix

## - A feasibility study




The linearity and detection limit can be determined for a quant method






# Even Better with High Power Instrument (TXS)



- 2% sample TXS 40KV 200ma
- 6.5% sample TXS 40KV 200ma
- amorphous sample TXS 40KV 200ma



# Sign of Crystalline Component?



Useful to detect the early sign of crystallization






# Differential Scanning Calorimetry

- **Detects the melting temperature and heat of fusion for crystalline component, and glass transition temperature (T<sub>g</sub>) for amorphous component**
- **Pros**
  - **Can be used as a quant method for crystallinity**
  - **Excellent tool for studying amorphous material's T<sub>g</sub> changes**
- **Cons**
  - **Sample homogeneity can be an issue**



# DSC Thermogram of A Two Component Pharmaceutical system





# Vibrational Spectroscopy


- **Secondary techniques**
- **Detects the short range local structural changes (probing the atomic interactions inside/between the molecules)**
- **Pros**
  - **Very sensitive tools for studying the interactions between the API molecules and co-processing agent or excipients for physical stability purpose**
  - **Can be used as a convenient tool for quant method or potentially for PAT applications**
- **Cons**
  - **Hardly been used alone**
  - **Data interpretation can be very challenging**





# Raman Spectrum

## - crystalline vs. amorphous API



The up-shift above 1640  $\text{cm}^{-1}$  of the amorphous material with respect to the crystalline material indicates that the amorphous material is likely to have a greater energy in the carbonyls and as such may be less hydrogen-bonded.





# ssNMR

- The primary tool to probe the material's structural changes
- It probes the specific nucleus and their inter-/intra-molecular environment; the spectroscopic change reflects the changes occurred in the immediate environment of the nucleus
- Pros
  - Should be very sensitive to the short range changes, especially by relaxation time measurements
  - A excellent tool for basic amorphous material understanding
  - Can be used as the quant method
- Cons
  - High level of expertise
  - Data interpretation can be very difficult
  - An expensive technique (instrument running time)









# ssNMR Spectra

- Crystalline vs. amorphous API\*



\* M. Tobyn, J. Brown, M. Fakes, Q. Gao, J. Gamble, Y. Khimyak, G. McGeorge, C. Patel, W. Sinclair, P. Timmins, S. Yin, *J. Pharm Sci*, in print.





# Conclusions

- **Pharmaceutical amorphous systems are very challenging, but can offer advantages if handled well**
- **The PXRD pattern of amorphous material reflects its “structure” features**
- **Any changes in amorphous PXRD patterns may represent the changes in the materials**
- **PXRD can be used as a primary technique for amorphous material studies**
- **Other physical characterization techniques probe the different structural properties of amorphous materials and should be used as the complementary tools**





# Acknowledgements

- **CJ Pommier (Ventana Medical Systems, Inc.)**
- **John DiMarco**
- **Mike Tobyn**
- **Gary McGeorge**
- **Chiajen Lai**
  
- **Holger Cordes, Bruker-AXS**

